Haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine Disease Interactions
There are 3 disease interactions with haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine.
Vaccines (applies to haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine) IM injection
Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect, Thrombocytopenia, Thrombocytopathy, Coagulation Defect
In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
References
- "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc PROD (2001):
- American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics (1997):
- "Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Havrix (HepA) (hepatitis A adult vaccine)." SmithKline Beecham PROD
- "Product Information. Engerix-B (HepB) (hepatitis B adult vaccine)." Apothecon Inc (2022):
- "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur (2005):
- "Product Information. ActHIB (Hib) (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur (2022):
- "Product Information. Imogam Rabies-HT (rabies immune globulin, human)." sanofi pasteur (2010):
- "Product Information. Hyperrab S/D (rabies immune globulin, human)." Grifols Therapeutics (2015):
- "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc (2022):
Meningococcal conjugate vaccine (applies to haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine) GBS
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome
Persons previously diagnosed with Guillain-Barre syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.
References
- "Product Information. Penbraya (cvx 316) (meningococcal group ACWY conjugate-group B vaccine (cvx 316))." Pfizer U.S. Pharmaceuticals Group (2024):
Vaccines (live attenuated/toxoid) (applies to haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
References
- "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur (2005):
- "Product Information. ActHIB (Hib) (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur (2022):
- "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc (2022):
- "Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group (2022):
- "Product Information. Hiberix (Hib) (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline (2022):
- "Product Information. Vaxchora (cholera vaccine, live)." PaxVax (2016):
- "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc (2022):
- "Product Information. Ixchiq (cvx 317) (chikungunya vaccine, live (cvx 317))." Valneva USA (2023):
Haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine drug interactions
There are 288 drug interactions with haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine.
More about haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine
- haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: bacterial vaccines
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.